However, TTX at five times the IC50 for Nav1.7 does not lead to enhanced enkephalin expression, suggesting that any compound that recapitulates the CIP phenotype of loss-of-function mutants will have to provide 100% Nav1.7 channel block, which is an unrealistic pharmacological goal. This evidence concerns the gene SCN9A and hereditary sensory and autonomic neuropathy.